Email steve@steveariens.com 502-938-2414
Pay Attention
By FDA law, compounding pharmacies are not allowed to compound and medications that is available as a commercially sold product. One exception is when a commercially produced product is in short supply or on back order. With these new GLP-1 medications, the very exact GLP-1 raw medication powder is NOT AVAILABLE to compounding pharmacies. Apparently […]
Filed under: General Problems | Leave a Comment »
Dr. Kolodny’s New Math: Turning Chronic Pain Patients into OUD Statistics https://www.acsh.org/news/2024/12/16/dr-kolodnys-new-math-turning-chronic-pain-patients-oud-statistics-49179 Just when you thought the opioid crisis may have peaked, Dr. Andrew Kolodny, arguably the world’s foremost anti-opioid zealot, has found a shiny new way to inflate the numbers. In the HHS’s redefining of opioid use disorder (OUD) to include patients responsibly taking […]
Filed under: General Problems | 7 Comments »
I asked www.perplexity.ai about what medications could be used for a pt with under/untreated intractable chronic pain. The AI’s response was all over the place – it was as if – this AI was an employee of CDC or PROP -but never mentioned the use of a opioid, but it did mention the use of […]
Filed under: General Problems | 3 Comments »
UnitedHealth Doctors Questioned https://www.medpagetoday.com/special-reports/features/113784 The U.S. Department of Justice (DOJ) is interviewing at least two former UnitedHealth Group physicians, two sources told STAT Both doctors had been interviewed for STAT’s series on UnitedHealth, and they described how patient care deteriorated after being acquired by Optum, a subsidiary of the healthcare giant. They also said they […]
Filed under: General Problems | 2 Comments »
Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says https://www.medpagetoday.com/washington-watch/washington-watch/113781 Three largest PBMs reimbursed own pharmacies at higher rates than independent ones, report finds The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from […]
Filed under: General Problems | Leave a Comment »
FDA Declares End to Tirzepatide Shortage While compounded GLP-1s served an important role during drug shortages, they are not considered identical to FDA-approved brand-name medications Mounjaro/Zepbound, Eli Lilly GLP-1 injectables are no longer in “short supply”. Thus compounding pharmacies can no longer legally compound it. Starting in 2025, once the Medicare pt pays $2,000 (deductibles […]
Filed under: General Problems | Leave a Comment »
what happens to the quality of patient care as private equity companies buy up companies that are providing health care? Here is a blog post that I made a few days ago about a large group of people that are finding difficulty in getting insurance to cover needed therapy. Imagine a disease so prevalent 40% […]
Filed under: General Problems | 1 Comment »
25 hospital closures in 2024 https://www.beckershospitalreview.com/finance/5-hospital-closures-in-2024.html Many hospitals and emergency departments have been forced to close in 2024 due to circumstances like high costs and shifts in care needs. Becker’s has reported on 25 hospital and emergency department closures in 2024: Editor’s note: This article was updated Dec. 27 at 3:06 p.m. CT. 1. ShorePoint Health […]
Filed under: General Problems | Leave a Comment »
Here is the “guidelines” for Ohio and prescribing opioids for Non-Terminal Pain. I did a “word search” for PHARMACOGENOMICS TESTING and it did not appear once in these guidelines. So these guidelines appears to be created by one or more people who is still functioning with a 20th century medical mind set/education. Just take a […]
Filed under: General Problems | 2 Comments »
CMS Moved to Expand Drug Coverage. Private Insurers Need to Step Up https://www.medpagetoday.com/opinion/second-opinions/113572 In July 2024, Joseph Zucchi, PA-C, MPAS, wrote about how stigma and misconceptions were creating barriers to GLP-1 obesity medication uptake, on top of systemic barriers like high costs and inadequate insurance coverage. As part of our review of the past year’s […]
Filed under: General Problems | 1 Comment »
